The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | A study comparing infection rates in patients treated with BCMA versus CD19-directed CAR-Ts
Muhammad Bilal Abid, MD, UT Houston McGovern School of Medicine, Houston, TX, discusses a study comparing infection rates in patients with relapsed/refractory (R/R) multiple myeloma who received BCMA-directed CAR T-cell therapy versus patients with large B-cell lymphoma (LBCL) who received CD19-directed therapy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
